Xenon Pharmaceuticals (XENE) Operating Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 10 years of Operating Margin data on file, last reported at 969.84% in Q1 2025.

• On a quarterly basis, Operating Margin changed N/A year-over-year to 969.84% in Q1 2025; TTM through Dec 2025 was 4974.27%, a N/A change from a year earlier, with the FY2025 full-year figure at 4974.27%, changed N/A from the prior year.
• Operating Margin for Q1 2025 stood at 969.84%, up from 28884.85% in the prior quarter.
• Over the last five years, Operating Margin for XENE reached as high as 192.0% in Q3 2021 and fell as low as 28884.85% in Q3 2022.
• Historically, Operating Margin has averaged 4743.51% across 3 years, with a median of 817.25% in 2021.
• On a YoY basis, Operating Margin climbed as much as 17035 bps in 2022 and fell as far as 2869285 bps in 2022.
• Year by year, Operating Margin stood at 664.65% in 2021, then sank by 4246 bps to 28884.85% in 2022, then surged by 97 bps to 969.84% in 2025.
• Per Business Quant data, the three most recent Operating Margin figures were 969.84% in Q1 2025, 28884.85% in Q3 2022, and 5655.78% in Q2 2022.